September 2020
Adding venetoclax to cladribine and low dose AraC alternating with 5-azacytdine in AML
In this podcast dr. Tapan Kadia discusses a phase II-study, evaluating the addition of venetoclax to cladribine plus low dose AraC alternating with 5-azacytidine in older patients with newly diagnosed acute myeloid leukaemia.
SUBSCRIBE TO BJH HEMATALKS SERIES
Top
